ライフサイエンスコーパス: Agilent

1 m designed to query CNVs at high resolution (Agilent).

2 rray platforms from Affymetrix, Illumina and Agilent.

3 arative genomic hybridization using a custom Agilent 1 M oligonucleotide array intended to cover 197

4 of our electroosmotic (EO)-driven HPLC with Agilent 1200 HPLC; comparable efficiencies, resolutions,

5 he onset of hypoxia was analysed using ovine Agilent 15.5k array and validated with qPCR and immunohi

6 genetic basis of this obesity syndrome using Agilent 185 k array comparative genomic hybridization (a

7 The Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alt

8 acted explosives were then analyzed with the Agilent 2100 Bioanalyzer lab on a chip device with minim

9 ulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform), as a novel approach

10 urine sediments was also assessed using the Agilent 2100 Bioanalyzer.

11 LabChip-based plasmid assay that runs on the Agilent 2100 Bioanalyzer.

12 from 17 tumors which were examined using the Agilent 44 k whole genome microarray.

13 Transthoracic power modulation images (Agilent 5500) were obtained during continuous intravenou

14 eries capillary columns housed in a standard Agilent 6890 gas chromatograph fitted with a high data a

15 from 11 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing

16 e impact of eight normalizations across both Agilent and Affymetrix expression platforms on three exp

17 ance of CNA detection by two high-resolution Agilent and Affymetrix microarray platforms.

18 Affymetrix and Illumina SNP array data with Agilent and fosmid clone end-sequencing results on eight

19 Agilent and Illumina are able to detect a greater total

20 ice with two different microarray platforms (Agilent and Illumina).

21 on of the three major platforms--Affymetrix, Agilent and Illumina.

22 atforms (the Mx3000P qPCR system [Stratagene-Agilent] and the 7500 real-time PCR system [ABI Life Tec

23 to and imports the native output files from Agilent, Applied Biosystems, Thermo Fisher Scientific an

24 we developed automated methods employing the Agilent AssayMAP Bravo microchromatography platform and

25 Results from IHC, PCR, RT-PCR, RNA Agilent Bioanalyser and Real-Time PCR showed that a nove

26 RNA integrity as assessed by Agilent Bioanalyzer, and amplification of the 28S riboso

27 The procedure used for Agilent Bond Elut DMS showed higher recoveries than the

28 rds was also performed (Whatman FTA DMPK and Agilent Bond Elut DMS) using elution procedures recommen

29 m Affymetrix GeneChips (MAS5/GCOS or dChip), Agilent Catalog or Custom arrays (using Agilent's Featur

30 cancer cell line derived RNA aliquots using Agilent cDNA and Affymetrix oligonucleotide microarray p

31 We applied this technology by coupling an Agilent Chemstation high-performance liquid chromatograp

32 ms, including strand-specific tiling arrays, Agilent custom expression arrays, strand-specific RNA-se

33 a range of model systems-IMS CCS standards (Agilent ESI Tune Mix), the monomeric protein Ubiquitin (

34 After adjusting Affymetrix data to mimic the Agilent experimental design (reference sample effect), w

35 ylation arrays [CHARM]) and gene expression (Agilent gene expression arrays) in 94 patients with IPF

36 ric patients and to test the accuracy of the Agilent Heartstream FR2 Patient Analysis System for sens

37 ailed sample preparation protocols, using an Agilent HPLC system, are described for Lys-C digestion o

38 This device works together with an Agilent HPLC-Chip to perform high-throughput nanoflow li

39 r commercial exome sequencing platforms from Agilent, Illumina and Nimblegen applied to the same huma

40 HT-12v3 from Illumina, Inc.; and 4112A from Agilent, Inc.

41 designed by our group and manufactured using Agilent inkjet technology.

42 The Agilent kits exhibit less precision than the ND-1000 spe

43 However, the Agilent kits require 1 microl of sample and can determin

44 used whole-genome transcript profiling using Agilent long-oligonucleotide microarrays representing 12

45 ere collected and RNA was analyzed using the Agilent microarray platform.

46 mbl transcripts mapped by Affymetrix(R); and Agilent microarray probes.

47 cular roles of Interferons on tumor, and the Agilent microarrays carrying tens of thousands of total

48 erated a wholly defined spike-in dataset for Agilent microarrays consisting of 12 arrays with more th

49 unohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 65

50 a and their transcriptome was analyzed using Agilent microarrays.

51 small RNA libraries and hybridization-based Agilent microarrays.

52 ted and genomic profiling was done using 22k Agilent microarrays.

53 croRNA expression profiles were generated by Agilent microRNA arrays.

54 Parallel analysis of microRNA with the Agilent miRNA microarray platform revealed that miR-142-

55 SCD = 7, controls = 7) by hybridizing to the Agilent miRNA microarrays.

56 In comparison, ion trap noise from Agilent MSD-Trap-SL is larger than the Q-TOF noise and i

57 etric approach has been used to optimize the Agilent multimode ion source.

58 This method uses the Agilent OFFGEL 3100 Fractionator and was optimized to pr

59 ated with Affymetrix 250K SNP arrays or 244K Agilent oligo-arrays and tested for inheritance from the

60 6J, DBA/2J, B6D2F1, and 37 BXD strains using Agilent oligonucleotide microarrays.

61 Data were collected using a custom designed Agilent oligonucleotide.

62 rray comparative genomic hybridization using Agilent platform, transcriptome sequencing using HiSeq 2

63 ree methods for the low-resolution data from Agilent platform.

64 NimbleGen and Agilent platforms outperformed Illumina and Affymetrix i

65 en results obtained using the Affymetrix and Agilent platforms.

66 which are not targeted by the Nimblegen and Agilent platforms.

67 si muscle gene expression was analyzed using Agilent porcine transcriptome microarrays and clusters o

68 range via an ND-1000 spectrophotometer (UV), Agilent RNA 6000 kits (MCE), and Quant-iT RiboGreen assa

69 Our analyses concluded that the Agilent's 60-mer oligonucleotide microarray with probe d

70 ip), Agilent Catalog or Custom arrays (using Agilent's Feature Extraction software) or data created b

71 tional exome capture technologies, including Agilent's SureSelect and NimbleGen's SeqCap, to generate

72 formed in 2 cousins in this family using the Agilent SureSelect Human all Exon 51 Mb version 5 captur

73 The genomic DNA was captured with the Agilent SureSelect Human All Exon kit, sequenced on the

74 Exome capture was performed by Agilent SureSelect V4, and sequencing was performed usin

75 We used the Agilent SureSelect XT2 protocol for library preparation,

76 sis of libraries of long oligonucleotides on Agilent Technologies' SurePrint DNA microarray platform.

77 roarrays were the platforms from Affymetrix, Agilent Technologies, Applied Biosystems, GE Healthcare,

78 was analyzed using 22,000-gene microarrays (Agilent Technologies, Palo Alto, CA).

79 The Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, Calif.) utilizes capill

80 interaction liquid chromatography as well as Agilent, Thermo Scientific, AB SCIEX, and LECO mass spec

81 by hybridizing petunia samples to a 4 x 44 K Agilent tomato array.

82 ( approximately 340 vs approximately 10) for Agilent tuning mix m/z 622 and 922 ions was achieved for

83 cs of three chromatographic silica products: Agilent Zorbax SB300, Waters Symmetry 300, and Merck Chr